Key facts
- It has raised $100K.
- Notable investors include Michael Banks.
- Ophthalmic Therapeutic Innovation has filed 1 Form D with the SEC, most recently Dec 2025 ($100K sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ophthalmic Therapeutic Innovation
- ·The full record, as it builds
Funding rounds
No funding rounds for Ophthalmic Therapeutic Innovation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ophthalmic Therapeutic Innovation
Developer of an MMP platform therapy and ophthalmic services intended to pioneer treatments for glaucoma. The company offers an adenosine-based drug, targeting the fundamental root causes of glaucoma, and is built upon a commitment to ethical practice and integrating clinical expertise, enabling clients to access breakthrough treatments that offer clearer vision and improve the quality of life for patients worldwide.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2023
- Employees
- 2
- Website
- ophthalmic-innovation.com/
- Ownership
- Privately Held (backing)
Ophthalmic Therapeutic Innovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ophthalmic Therapeutic Innovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ophthalmic Therapeutic Innovation in its N-PORT filings yet. We sweep new filings monthly.